Compass Pathways Plc | Blossom Social

Portfolio0% of Portfolio

Price Gain

Dividends

Returns

Investors165 holders & 28 watchers

Market MovesTrades in the last 30 days

22 Bought

26 Sold

Financials

Market Cap$2B

Dividend Yield0.00%

P/E Ratio--

EPS-3.14

Volume4M

Beta2.487

MER--

AUM$0.00

About

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Popular Posts

Posts

Trades

News

All

Join the conversation with 500,000+ other investors 💸

Create an account to get access to everything Blossom has to offer!

📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in

Sign up I have an account

Portfolio0% of Portfolio

Price Gain

Dividends

Returns

Financials

Market Cap$2B

Dividend Yield0.00%

P/E Ratio--

EPS-3.14

Volume4M

Beta2.487

MER--

AUM$0.00

About

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.